Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 01 2021
Historique:
received: 05 03 2020
accepted: 21 12 2020
entrez: 13 1 2021
pubmed: 14 1 2021
medline: 26 8 2021
Statut: epublish

Résumé

Since colorectal cancer (CRC) remains one of the most common malignancies, a tremendous amount of studies keep taking place in this field. Over the past 25 years, a notable part of the scientific community has focused on the association between the immune system and colorectal cancer. A variety of studies have shown that high densities of infiltrating CD8+ T-cells are associated with improved disease-free and overall survival in CRC. Stromal cell-derived factor-1 (SDF-1) is a protein that regulates leukocyte trafficking and is variably expressed in several healthy and malignant tissues. There is strong evidence that SDF-1 has a negative prognostic impact on a variety of solid tumors. However, the existing data do not provide sufficient evidence that the expression of SDF-1 has an influence on CRC. Knowing nowadays, that the microenvironment plays a crucial role in the development of cancer, we hypothesized that the expression of SDF-1 in CRC could influence the prognostic significance of CD8+ T-cells, as an indicator of the essential role of the immune microenvironment in cancer development. Therefore, we explored the combined prognostic significance of CD8+ T-cell density and SDF-1 expression in a large CRC collective. We analyzed a tissue microarray of 613 patient specimens of primary CRCs by immunohistochemistry (IHC) for the CD8 + T-cells density and the expression of SDF-1 by tumor cells and tumor-infiltrating immune cells. Besides, we analyzed the expression of SDF-1 at the RNA level in The Cancer Genome Atlas cohort. We found that the combined high CD8+ T-cell infiltration and expression of SDF-1 shows a favorable 5-year overall survival rate (66%; 95% CI 48-79%) compared to tumors showing a high expression of CD8+ T-cell only (55%; 95% CI 45-64%; p = 0.0004). After stratifying the patients in nodal negative and positive groups, we found that the prognostic significance of CD8+ T-cell density in nodal positive colorectal cancer depends on SDF-1 expression. Univariate and multivariate Hazard Cox regression survival analysis considering the combination of both markers revealed that the combined high expression of SDF-1 and CD8+ T-cell density was an independent, favorable, prognostic marker for overall survival (HR = 0.34, 95% CI 0.17-0.66; p = 0.002 and HR = 0.45, 95% CI 0.23-0.89; p = 0.021, respectively). In our cohort there was a very weak correlation between SDF-1 and CD8+ T-cells (r

Identifiants

pubmed: 33436863
doi: 10.1038/s41598-020-80382-2
pii: 10.1038/s41598-020-80382-2
pmc: PMC7803998
doi:

Substances chimiques

CXCL12 protein, human 0
Chemokine CXCL12 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

775

Références

Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Eur J Cancer. 2009 Sep;45(14):2579-87
pubmed: 19646861
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2018 Jul 26;379(4):396-397
pubmed: 30044940
Ann Surg Oncol. 2007 Nov;14(11):3154-8
pubmed: 17653799
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Cancer Biomark. 2015;15(6):869-79
pubmed: 26406413
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Oncotarget. 2016 Sep 20;7(38):62006-62018
pubmed: 27542220
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
PLoS One. 2014 Mar 04;9(3):e90400
pubmed: 24594697
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
J Exp Med. 1996 Sep 1;184(3):1101-9
pubmed: 9064327
J Clin Pathol. 2007 Oct;60(10):1112-6
pubmed: 17182662
Br J Cancer. 2003 Aug 4;89(3):431-6
pubmed: 12888808
Oncotarget. 2015 Nov 10;6(35):37588-99
pubmed: 26439988
Br J Cancer. 2004 Nov 1;91(9):1711-7
pubmed: 15494715
Lancet Oncol. 2007 Jul;8(7):651-7
pubmed: 17613427
PLoS One. 2010 Dec 10;5(12):e14282
pubmed: 21179245
J Clin Pathol. 2008 May;61(5):561-9
pubmed: 18326017
J Clin Oncol. 2011 Feb 20;29(6):601-3
pubmed: 21245434
Br J Cancer. 2017 Jun 27;117(1):124-135
pubmed: 28535157
PLoS One. 2013 May 29;8(5):e64814
pubmed: 23734221
Dis Colon Rectum. 2017 Oct;60(10):999-1017
pubmed: 28891842
Oncoimmunology. 2015 May 29;4(12):e1050574
pubmed: 26587320
Hum Pathol. 2004 Jul;35(7):808-16
pubmed: 15257543
Lancet Oncol. 2017 Jul;18(7):849-851
pubmed: 28677562
Clin Exp Metastasis. 2012 Feb;29(2):101-10
pubmed: 22075627
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Am J Clin Pathol. 2009 Aug;132(2):202-10; quiz 307
pubmed: 19605814
Virchows Arch. 2016 Apr;468(4):463-71
pubmed: 26818832
Dis Markers. 2014;2014:792183
pubmed: 25609852
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Oncogene. 2016 Feb 18;35(7):816-26
pubmed: 25961926
Nat Rev Drug Discov. 2003 Dec;2(12):962-72
pubmed: 14654795
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Immunol Today. 2000 Dec;21(12):630-6
pubmed: 11114424
Cell Oncol (Dordr). 2017 Dec;40(6):609-619
pubmed: 28936810
Clin Cancer Res. 2004 Jul 1;10(13):4450-6
pubmed: 15240536
Tumour Biol. 2016 Jun;37(6):7441-52
pubmed: 26678887
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
pubmed: 12626353

Auteurs

Alexandros Lalos (A)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland. alexandroslalos7@gmail.com.

Ali Tülek (A)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.

Nadia Tosti (N)

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.

Robert Mechera (R)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.

Alexander Wilhelm (A)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.

Savas Soysal (S)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.

Silvio Daester (S)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.

Venkatesh Kancherla (V)

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.

Benjamin Weixler (B)

Department of Surgery, Charité University Hospital, Campus Benjamin Franklin, Berlin, Germany.

Giulio C Spagnoli (GC)

Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

Serenella Eppenberger-Castori (S)

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.

Luigi Terracciano (L)

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.

Salvatore Piscuoglio (S)

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.
Visceral Surgery Research Laboratory, Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland.

Markus von Flüe (M)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.
Visceral Surgery Research Laboratory, Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland.

Alberto Posabella (A)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.

Raoul A Droeser (RA)

University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland. RaoulAndre.Droeser@clarunis.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH